DOCSLIB.ORG

Slone Program Publications List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Slone Program Publications List Slone Epidemiology Center at Boston University Program Publication List 1. Hartz SC, Heinonen OP, Shapiro S, Siskind V, Slone D. Antenatal exposure to meprobamate and chlordiazexopide in relation to malformations, mental development, and childhood mortality. N Engl J Med 1975;292:726-8. 2. Mitchell AA, Goldman P, Shapiro S, Siskind V, Slone D. Intensive drug surveillance in a pediatric hospital. In: Gouveia WS, Tognoni G, Van der Kleijn E, eds. Clinical pharmacy and clinical pharmacology. Amsterdam: Elsevier/North-Holland Biomedical Press, 1976:311- 7. 3. Shapiro S, Slone D, Hartz SC, Rosenberg L, Siskind V, Monson RR, Mitchell AA, Heinonen OP, Idanpaan-Heikkila J, Haro S, Saxon L. Anticonvulsants and parental epilepsy in the development of birth defects. Lancet 1976;1:272-5. 4. Slone D, Heinonen OP, Kaufman DW, Siskind V, Monson RR, Shapiro S. Aspirin and congenital malformations. Lancet 1976;1:1373-8. 5. Shapiro S, Siskind V, Heinonen OP, Monson RR, Kaufman DW, Slone D. Perinatal mortality and birth weight in relation to aspirin taken during pregnancy. Lancet 1976;1:1375- 6. 6. Slone D, Shapiro S, Heinonen OP, Monson RR, Hartz SC, Siskind V, Rosenberg L, Mitchell AA. Maternal drug exposure and birth defects. In: Birth defects: risks and consequences. New York: Academic Press, 1976:265-74. 7. Senior B, Slone S, Shapiro S, Mitchell AA, Heinonen OP. Benzothiadiazides and neonatal hypoglycaemia [letter to the editor]. Lancet 1976;2:377. 8. Swett C, Cole JO, Hartz SC, Shapiro S, Slone D. Hypotension due to chlorpromazine. Arch Gen Psychiatry 1977;34:661-3. 9. Heinonen OP, Slone D, Monson RR, Hook EB, Shapiro S. Cardiovascular birth defects and antenatal exposure to female sex hormones. N Engl J Med 1977;296:67-70. 10. Shapiro S, Heinonen OP, Siskind V, Kaufman DW, Monson RR, Slone D. Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Bendectin) in relation to congenital malformations, perinatal mortality rate, birth weight and intelligence quotient score. Am J Obstet Gynecol 1977;128:480-5. 11. Slone D, Siskind V, Heinonen OP, Monson RR, Kaufman D, Shapiro S. Antenatal exposure to the phenothiazines in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977;128:486-8. 12. Slone D, Shapiro S, Miettinen OS. Case-control surveillance of serious illnesses attributable to ambulatory drug use. In: Colombo F, Shapiro S, Slone D, Tognoni G, eds. Epidemiological evaluation of drugs. Amsterdam: Elsevier/North Holland Biomedical Press, 1977:59-70. 13. Miettinen OS, Slone D, Shapiro S. Current problems in drug-related epidemiologic research. In: Colombo F, Shapiro S, Slone D, Tognoni G, eds. Epidemiological evaluation of drugs. Amsterdam: Elsevier/North Holland Biomedical Press, 1977:295-303. 14. Shapiro S, Slone D. Case-control surveillance. In: Gross FH, Inman HW, eds. Drug monitoring. London: Academic Press, 1977:33-48. 15. Shapiro S, Slone D, Hartz SC, Rosenberg L, Siskind V, Monson RR, Mitchell AA, Heinonen OP. Are hydantoins (phenytoins) human teratogens? [letter to the editor]. J Pediatr 1977;90:673-5. 16. Shapiro S, Kaufman DW, Rosenberg L, Slone D, Monson RR, Siskind V, Heinonen OP. Meclizine in pregnancy in relation to congenital malformations. BMJ 1978;1:483. 17. Slone D, Shapiro S, Rosenberg L, Kaufman DW, Hartz SC, Rossi AC, Stolley PD, Miettinen OS. Relation of cigarette smoking to myocardial infarction in young women. N Engl J Med 1978;298:1273-6. 18. Stolley PD, Shapiro S, Slone D, Schinnar R. Cardiovascular effects of oral contraceptives. South Med J 1978;71:821-4. 19. Slone D, Shapiro S, Miettinen OS, Finkle WD, Stolley PD. Drug evaluation after marketing: a policy perspective. Ann Intern Med 1979;90:257-61. 20. Shapiro S, Slone D, Rosenberg L, Kaufman DW, Stolley PD, Miettinen OS. Oral- contraceptive use in relation to myocardial infarction. Lancet 1979;1:743-7. 21. Rosenberg L, Shapiro S, Kaufman DW, Slone D, Miettinen OS, Stolley PD. Patterns and determinants of conjugated estrogen use. Am J Epidmiol 1979;109:676-86. 22. Mitchell AA, Goldman P, Shapiro S, Slone D. Drug utilization and reported adverse reactions in hospitalized children. Am J Epidemiol 1979;110:196-204. 23. Stolley PD, Davies JL, Shapiro S, Slone D. Components of an epidemiological system for the surveillance of adverse effects due to vaginal contraceptives. In: Zatuchni GI, Sobrero AJ, Speidel JJ, Sciarra JJ, eds. Vaginal contraceptives: new developments. Hagerstown, MD: Harper & Row, 1979:271-6. 24. Shapiro S, Slone D. The effects of exogenous female hormones on the fetus. Epidemiol Rev 1979;1:110-23. 25. Lacouture PG, Mitchell AA, Lovejoy FH. Thiethylperazine (Torecan)-associated dystonic reactions in children. Pediatrics 1979;64:954-5. 26. Shapiro S, Slone D. The effects of exogenous female sex hormones on the fetus. Epidemiol Rev 1979;1:110-23. 27. Slone D, Shapiro S, Mitchell AA. Strategies for studying the effects of the antenatal chemical environment on the fetus. In: Schwarz RH, Yaffe SJ, eds. Drug and chemical risks to the fetus and newborn. New York: Alan R. Liss, Inc., 1980. 28. Rosenberg L, Kaufman DW, Shapiro S, Slone D. Cigarette smoking and risk of premature myocardial infarction. Prim Cardiol 1980;6:11-5. 29. Rosenberg L, Slone D, Shapiro S, Kaufman DW, Stolley PD, Miettinen OS. Coffee drinking and myocardial infarction in young women. Am J Epidemiol 1980;111:675-81. 30. Kaufman DW, Shapiro S, Rosenberg L, Monson RR, Miettinen OS, Stolley PD, Slone D. Intrauterine contraceptive device use and pelvic inflammatory disease. Am J Obstet Gynecol 1980;136:159-62. 31. Rosenberg L, Shapiro S, Kaufman DW, Slone D, Miettinen OS, Stolley PD. Cigarette smoking in relation to the risk of myocardial infarction in young women: modifying influence of age and predisposing factors. Int J Epidemiol 1980;9:57-63. 32. Kaufman DW, Slone D, Rosenberg L, Miettinen OS, Shapiro S. Cigarette smoking and age at natural menopause. Am J Public Health 1980;70:420-2. 33. Rosenberg L, Slone D, Shapiro S, Kaufman DW, Stolley PD, Miettinen OS. Noncontraceptive estrogens and myocardial infarction in young women. J Am Med Assoc 1980;244:339-42. 34. Shapiro S, Kaufman DW, Slone D, Rosenberg L, Miettinen OS, Stolley PD, Rosenshein NB, Watring WG, Leavitt T, Knapp RC. Recent and past use of conjugated estrogens in relation to adenocarcinoma of the endometrium. N Engl J Med 1980;303:485-9. 35. Rosenberg L, Shapiro S, Slone D, Kaufman DW, Miettinen OS, Stolley PD. Thiazides and acute cholecystitis. N Engl J Med 1980;303:546-8. 36. Shapiro S, Slone D, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD, Knapp RC, Leavitt T, Watring WG, Rosenshein NB, Schottenfeld D. Use of thyroid supplements in relation to breast cancer. J Am Med Assoc 1980;244:1685-7. 37. Hartz SC, Shapiro S, Kaufman DW, Rosenberg L, Slone D. Factors associated with oral contraceptive use. Am J Public Health 1980;70:1105-8. 38. Kaufman DW, Shapiro S, Slone D, Rosenberg L, Miettinen OS, Stolley PD, Knapp RC, Leavitt T, Watring WG, Rosenshein NB, Lewis JL, Schottenfeld D, Engle RL. Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med 1980;303:1045-7. 39. Mitchell AA, Slone D, Shapiro S, Goldman P. Adverse drug effects and drug surveillance. In: Yaffe SJ, ed. Pediatric pharmacology therapeutic principles in practice. New York: Grune & Stratton, Inc., 1980:65-78. 40. Rosenberg L, Slone D, Shapiro S, Kaufman DW, Miettinen OS, Stolley PD. Alcoholic beverages and myocardial infarction in young women. Am J Public Health 1981;71:82-4. 41. Mitchell AA, Rosenberg L, Shapiro S, Slone D. Birth defects related to Bendectin use in pregnancy: oral clefts and cardiac defects. J Am Med Assoc 1981;245:2311-4. 42. Rosenberg L, Slone D, Shapiro S, Kaufman DW, Miettinen OS. Case-control studies on the acute effects of coffee upon the risk of myocardial infarction: problems in the selection of a hospital control series. Am J Epidemiol 1981;113:646-52. 43. Slone D, Shapiro S, Kaufman DW, Rosenberg L, Miettinen OS, Stolley PD. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981;305:420-4. 44. Rosenberg L, Slone D, Shapiro S, Kaufman DW, Helmrich SP, Miettinen OS, Stolley PD, Levy M, Rosenshein NB, Schottenfeld D, Engle RL. Breast cancer and alcoholic-beverage consumption. Lancet 1982;1:267-70. 45. Kaufman DW, Slone D, Shapiro S, Rosenberg L, Helmrich SP, Miettinen OS, Stolley PD, Levy M, Schottenfeld D. Diazepam and the risk of breast cancer. Lancet 1982;1:537-9. 46. Rosenberg L, Mitchell AA, Shapiro S, Slone D. Selected birth defects in relation to caffeine- containing beverages. J Am Med Assoc 1982;247:1429-32. 47. Rosenberg L, Slone D, Shapiro S, Kaufman DW, Miettinen OS, Stolley PD. Aspirin and myocardial infarction in young women. Am J Public Health 1982;72:389-91. 48. Shapiro S, Slone D, Heinonen OP, Kaufman DW, Rosenberg L, Mitchell AA, Helmrich SP. Birth defects and vaginal spermicides. J Am Med Assoc 1982;247:2381-4. 49. Mitchell AA, Louik C, Lacouture P, Slone D, Goldman P, Shapiro S. Risks to children from computed tomographic scan premedication. J Am Med Assoc 1982;247:2385-8. 50. Rosenberg L, Shapiro S, Slone D, Kaufman DW, Helmrich SP, Miettinen OS, Stolley PD, Rosenshein NB, Schottenfeld D, Engle RL. Epithelial ovarian cancer and combination oral contraceptives. J Am Med Assoc 1982;247:3210-2. 51. Mitchell AA, Lovejoy FH, Slone D, Shapiro S. Acetaminophen and aspirin: prescription, use, and accidental ingestion among children. Am J Dis Child 1982;136:976-9. 52. Mitchell AA, Hartz SC, Shapiro S, Slone D.
Load more

Recommended publications
  • Clinical Evaluation of Pipecuronium Bromide and Its Comparison With
    Scholars Journal of Applied Medical Sciences (SJAMS) ISSN 2320-6691 (Online) Sch. J. App. Med. Sci., 2013; 1(6):943-950 ISSN 2347-954X (Print) ©Scholars Academic and Scientific Publisher (An International Publisher for Academic and Scientific Resources) www.saspublisher.com Research Article Clinical Evaluation of Pipecuronium Bromide and its Comparison with Pancuronium Bromide Kaushal RP Associate Professor, Department of cardiac anesthesia, Gandhi Medical College, Bhopal, India. *Corresponding author Kaushal RP Email: Abstract: The study was carried out to compare the intubating conditions, cardiovascular responses, neuro-muscular blocking properties and reversal characteristics of pipecuronium bromide and pancuronium bromide. This is a prospective hospital based study. 100 patients belonging to ASA grade I or II physical status aged 18 to 70 years were divided into two groups of 50 patients each. Group 1 received pipecuronium bromide in the dose of .08 mg / kg and group 2 patients received pancuronium bromide in dose of 0.1 mg/kg. Each patient was pre medicated uniformly. Time for onset of apnoea for pipecuronium and pancuronium were 91.64+ 3.59 sec. and 118.84 + 12.53 sec. respectively. The mean time for intubation was 126.60 +12.55 sec. and 144.60 + 22.87 sec. with pipecuronium and pancuronium respectively. Mean duration of block for pipecuronium was 78.64 + 8.97 min. the block for pancuronium lasted from +36-40 min with a mean duration of block 41.60+ 5.57 min. The mean duration of maintenance dose in pipecuronium cases was 45.08 + 7.19 min., while it was 27.06 + 5.01 min in pancuronium cases.
    [Show full text]
  • Pancuronium Bromide (Pavulon | Evaluation of Its Clinical Pharmacology*
    PANCURONIUM BROMIDE (PAVULON | EVALUATION OF ITS CLINICAL PHARMACOLOGY* ALLEN B. DOBKIN, M.D., WILLIAM EVEBS,M.D., SION GHANOONI, M.D., ASHLEYA. LEVY, VH.D., AND EDWARDT. THOMAS,M.B. PANCURONIUMBROMIDE IS AN amino steroid muscle relaxant (Figure 1) which was synthesized in 1964 by Hewett and Savage and has been studied and evaluated clinically in Europe during the past four years2-5 It is an odourless, white, crystal- line powder with a bitter astringent taste, melts at 215~ with decomposition, and is soluble in 50 parts of chloroform and one part water at 20~ The co]ourless solution is stable while sealed, but breaks down in a few hours after exposure to air. In Europe it is available in 2-ml ampoules containing 4 mg pancuronium bro- mide, 18 nag sodium chloride B.P. and water for injection B.P. to 2 mls. The prepara- tion which was used in this study contains preservatives (acetic acid and sodium acetate) to buffer the solution to pH 4.0. OOC.CH 3N~~ 2BP- CH3CO0 H H20 -- Pancur'ontum Bromide - Pavuton (R) FIGURE 1. Structural formula for paneuronium bromide - Pavulon| Pharmacological studies have shown that it has no hormonal action but is a potent non-depolarizing skeletal muscle relaxant like'tubocurarine and gallamine. It has a more rapid onset of action than tubocurarine with a similar duration of action. It has a somewhat longer action than gallamine. It has no significant effect on the blood pressure or the tracheobronchial tree due to the very. slight ganglion- blocking action and the claim is that no histamine is released, a It does not affect *From the Department of Anesthesiology, State University Itospital, State University of New York, Upstate Medical Center, Syracuse, New York, 13210, U.S.A.
    [Show full text]
  • Malta Medicines List April 08
    Defined Daily Doses Pharmacological Dispensing Active Ingredients Trade Name Dosage strength Dosage form ATC Code Comments (WHO) Classification Class Glucobay 50 50mg Alpha Glucosidase Inhibitor - Blood Acarbose Tablet 300mg A10BF01 PoM Glucose Lowering Glucobay 100 100mg Medicine Rantudil® Forte 60mg Capsule hard Anti-inflammatory and Acemetacine 0.12g anti rheumatic, non M01AB11 PoM steroidal Rantudil® Retard 90mg Slow release capsule Carbonic Anhydrase Inhibitor - Acetazolamide Diamox 250mg Tablet 750mg S01EC01 PoM Antiglaucoma Preparation Parasympatho- Powder and solvent for solution for mimetic - Acetylcholine Chloride Miovisin® 10mg/ml Refer to PIL S01EB09 PoM eye irrigation Antiglaucoma Preparation Acetylcysteine 200mg/ml Concentrate for solution for Acetylcysteine 200mg/ml Refer to PIL Antidote PoM Injection injection V03AB23 Zovirax™ Suspension 200mg/5ml Oral suspension Aciclovir Medovir 200 200mg Tablet Virucid 200 Zovirax® 200mg Dispersible film-coated tablets 4g Antiviral J05AB01 PoM Zovirax® 800mg Aciclovir Medovir 800 800mg Tablet Aciclovir Virucid 800 Virucid 400 400mg Tablet Aciclovir Merck 250mg Powder for solution for inj Immunovir® Zovirax® Cream PoM PoM Numark Cold Sore Cream 5% w/w (5g/100g)Cream Refer to PIL Antiviral D06BB03 Vitasorb Cold Sore OTC Cream Medovir PoM Neotigason® 10mg Acitretin Capsule 35mg Retinoid - Antipsoriatic D05BB02 PoM Neotigason® 25mg Acrivastine Benadryl® Allergy Relief 8mg Capsule 24mg Antihistamine R06AX18 OTC Carbomix 81.3%w/w Granules for oral suspension Antidiarrhoeal and Activated Charcoal
    [Show full text]
  • Clinical Pharmacokinetics of Muscle Relaxants
    i ,I .. / ,""- Clinical Pharmacokinetics 2: 330-343 (1977) © ADIS Press 1977 Clinical Pharmacokinetics of Muscle Relaxants L.B. Wingard and DR. Cook Departments of Pharmacology and Anesthesiology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania SUl1lmary Muscle relaxants are commonly used as an adjunct to general anaesthesia and to facilitate ventilator care in the intensive care unit. The muscle relaxants are unique in that the degree of neurol1luscular blockade can be directly measured. Thus, for some of the muscle relaxants it is possible to correlate the degree of neuromuscular blockade with the plasma concentration of drug. This quantilalive pllGrmacokinelic approach has been applied primarily to d­ tubocurarine and to a lesser extent to suxamethonium (succinylcholine), gallamine and pan­ curoniul1l. The pharl1lacokinetic information for the other relaxants is mostly descriptive and incomplete. The variation in drug concentration over time is in.fluenced by the distribution, metabolism and excretion of drug. Metabolism by plasma cholinesterase plays a maJor role in the termina­ tion (~f action of suxamethonium. Although pancuronium is partly metabolised its major metabolites have moderate pharmacological activity. The other relaxants are excreted through the kidney. For gallamine and dimethyl-tubocurarine, renal excretion appears to be the only means qf eliinination. However, biliary excretion probably provides an alternative route of elimination for d-tubocurarine and pancuronium. In patients with impaired renal function the duration qf neuromusClilar blockade may be markedly prolonged following standard doses of gallamine or dimethyl-tubocurarine, may be slightly prolonged following standard doses of pancumnium, and is near normal following standard doses qf d-tubocurarine. Following large or repeated doses q(pancuronium or d-tubocurarine, the duration q{ neuromuscular blockade may be markedly prolonged.
    [Show full text]
  • Inhibitory Actions of Vecuronium Bromide on Acetylcholine and Glutamate Responses at the Frog and Crayfish Neuromuscular Junction
    Inhibitory Actions of Vecuronium Bromide on Acetylcholine and Glutamate Responses at the Frog and Crayfish Neuromuscular Junction Haruhiko SHINOZAKI and Michiko ISHIDA The Tokyo Metropolitan Institute of Medical Science, 3-18-22 Honkomagome, Bunkyo-ku, Tokyo 113, Japan Accepted November 7, 1983 Abstract-Effects of vecuronium bromide, an analog of pancuronium, on the cholinergic and glutamatergic neuromuscular junction were investigated. Vecuronium depressed the postsynaptic response of the frog end-plate at lower concentrations than 10-6 g/ml without affecting the presynaptic events. Vecuronium decreased the amplitude of the double ACh potential, but the second potential was more markedly reduced than the first. In analogy with d-tubocurarine, this suggests that vecuronium may act in part as an open channel blocker at the frog end-plate. Vecuro nium depressed both the glutamate response and the excitatory junctional potential at the crayfish neuromuscular junction, although high concentrations were required. The drug increased the decay rate of extracellularly recorded excitatory functional potentials at the crayfish neuromuscular junction. The reduction of the crayfish synaptic response caused by vecuronium can be explained by the open channel blocking action at this functional site. The problem that cholinergic antagonists possess a property of channel blocking at the other transmitter system was discussed. Vecuronium is an analog of pancuronium, The neuromuscular blocking action of pan but is not the bis-quarternary ammonium, one curonium has been well documented (2). quarternary moiety of pancuronium being The comparison of pharmacological activities replaced by a tertiary amine (Fig. 11. Although of vecuronium to pancuronium was already it is known that replacement of one quar done in some earlier studies (3-6), and ternary moiety of the bis-quarternary am the effectiveness of both drugs is almost monium structure by a primary amine group the same, however, electrophysiological results in a considerable loss of potency (1), studies are lacking.
    [Show full text]
  • Summary of Product Characteristics
    Health Products Regulatory Authority Summary of Product Characteristics 1 NAME OF THE MEDICINAL PRODUCT Pancuronium Bromide 2 mg/ml Solution for Injection 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml contains 2 mg of pancuronium bromide. Each 2 ml ampoule contains 4 mg of pancuronium bromide. Excipients with known effect: For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Solution for injection. A clear, colourless solution with a pH of 3.8 – 4.2. 4 CLINICAL PARTICULARS 4.1 Therapeutic Indications Pancuronium bromide is a neuromuscular blocking agent with a long duration of action. It is used as an adjuvant in surgical anaesthesia to obtain relaxation of the skeletal muscles in a wide range of surgical procedures. It is also used as relaxant in orthopaedic manipulations. Used in intensive care therapy for a variety of pathologies e.g. intractable status asthmaticus and tetanus. 4.2 Posology and method of administration Posology The use of a peripheral nerve stimulator is recommended for monitoring the neuromuscular block and recovery. The following may be used as a guideline: ADULT: Initial dose: 50-80 micrograms/kg (intubation within 150 to 120 seconds) Or 80-100 micrograms/kg (intubation accomplished within 120-90 seconds). Incremental doses: 10-20 micrograms/kg PAEDIATRIC: Initial dose: 60-100 micrograms/kg Incremental doses: 10-20 micrograms/kg NEONATES: Initial dose: 30-40 micrograms/kg Incremental doses: As neonates are sensitive this dose should be adjusted according to the initial response but generally incremental doses lie in the range 10 to 20 micrograms/kg. Ifsuxamethonium is used for intubation, the administration of pancuronium bromide should be delayed until the patient has clinically recovered from the neuromuscular block induced by suxamethonium.
    [Show full text]
  • Prescribing Information Pancuronium Bromide
    PRESCRIBING INFORMATION PANCURONIUM BROMIDE INJECTION ABBOTT Standard 1 mg/mL Vials and 2 mg/mL Ampoules Nondepolarizing Neuromuscular Blocking Agent Hospira Healthcare Corporation Control#: 162429 1111 Dr.-Frederik-Philips Blvd., Suite 600 Saint-Laurent (Quebec) H4M 2X6 DATE OF REVISION: May 21, 2013 PRESCRIBING INFORMATION NAME OF DRUG PANCURONIUM BROMIDE INJECTION ABBOTT Standard 1 mg/mL Vials and 2 mg/mL Ampoules THERAPEUTIC CLASSIFICATION Nondepolarizing Neuromuscular Blocking Agent ACTION AND CLINICAL PHARMACOLOGY PANCURONIUM BROMIDE INJECTION is a nondepolarizing neuromuscular blocking agent possessing all of the characteristic pharmacological actions of this class of drugs (curariform). It acts by competing for cholinergic receptors at the motor end-plate. The antagonism to acetylcholine is inhibited and neuromuscular block is reversed by anticholinesterase agents such as pyridostigmine, neostigmine, and edrophonium. Pancuronium is approximately 1/3 less potent than vecuronium and approximately 5 times as potent as d-tubocurarine: the duration of neuromuscular blockade produced by pancuronium is longer than that of vecuronium at initially equipotent doses. The onset and duration of action of pancuronium are dose-dependent. The ED (dose required 95 to produce 95% suppression of muscle twitch response) is approximately 0.05 mg/kg under balanced anesthesia and 0.03 mg/kg under halothane anesthesia. These doses produce effective skeletal muscle relaxation (as judged by time from maximum effect to 25% recovery of control twitch height) for approximately 22 minutes: the duration from injection to 90% recovery of control twitch height is approximately 65 minutes. The intubating dose of 0.1 mg/kg (balanced anesthesia) will effectively abolish twitch response within approximately 4 minutes: time from injection to 25% recovery from this dose is approximately 100 minutes.
    [Show full text]
  • So Long As They Die Lethal Injections in the United States
    April 2006 Volume 18, No. 1(G) So Long as They Die Lethal Injections in the United States Summary......................................................................................................................................... 1 Recommendations......................................................................................................................... 7 To State and Federal Corrections Agencies.......................................................................... 7 To State Legislators and the U.S. Congress.......................................................................... 8 I. Development of Lethal Injection Protocols ......................................................................... 9 Oklahoma.................................................................................................................................13 Texas.........................................................................................................................................15 Tennessee.................................................................................................................................17 Lethal Injection Machines .....................................................................................................18 Public Access to Lethal Injection Protocols.......................................................................20 II. Lethal Injection Drugs ..........................................................................................................21 Potassium Chloride.................................................................................................................22
    [Show full text]
  • Download Leaflet View the Patient Leaflet in PDF Format
    Package leaflet: Information for the user Pancuronium Bromide 2 mg/ml Solution for Injection pancuronium bromide Read all of this leaflet carefully before you start using this medicine because it contains important information for you. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor, pharmacist or nurse. • If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Pancuronium Bromide Solution for Injection is and what it is used for 2. What you need to know before you use Pancuronium Bromide Solution for Injection 3. How to use Pancuronium Bromide Solution for Injection 4. Possible side effects 5. How to store Pancuronium Bromide Solution for Injection 6. Contents of the pack and other information 1. What Pancuronium Bromide Solution for Injection is and what it is used for Pancuronium bromide is one of a group of medicines called ‘non-depolarising’ muscle relaxants. Pancuronium bromide solution for injection is used to relax muscles during surgery, including caesarean section and in intensive care. You must talk to a doctor if you do not feel better or if you feel worse. 2. What you need to know before you use Pancuronium Bromide solution for injection Do not use Pancuronium Bromide Solution for Injection if you are allergic to pancuronium bromide or any of the ingredients of this medicine (listed in section 6. Warning and precautions Talk to your doctor or
    [Show full text]
  • Subject Index to Abstracts
    003 1-3998/85/1904-44 lA$02.00 Vol. 19, No. 4, 1985 PEDIATRIC RESEARCH Printed in U.S.A. Copyright O 1985 International Pediatric Research Foundation,Inc. SUBJECT INDEX TO ABSTRACTS 1,25 (OH)2 D 1200 ADENOSINE DEAMINASE 909, 962, ALCOHOLISM 514 1,25 DIHYDROXYVITAMIN D3 973 967 ALDOSTERONE 333, 334, 808, 1,251 DIHYDROXYVITAMIN D 1223, ADENOSINE TRIPHOSPHATASE 323, 1591, 1605 1681 1571 ALKALINE PHOSPHATASE 728, 1200 14C DEOXYGLUCOSE 1316 ADENOSINE TRIPHOSPHATE 90, 98, ALKALOSIS 796 17 HYDROXYPROGESTERONE 436 860, 1600 ALKALOSIS, RESPIRATORY 1409 21 HYDROXYLASE DEFICIENCY 861 ADENOTONSILLECTOMY 1725 ALLERGY 652 21 HYDROXYLASE DEFICIENCY, ADENOVIRUS INFECTIONS 950 ALLOGENEIC 1018 NONCLASSICAL 861 ADENOVIRUSES, HUMAN 585 ALLOGRAFT REJECTION 1647 24 HOUR 440 ADENYL CYCLASE 277, 439, 1592 ALLOGRAFTS 1593, 1593 24 HYDROXYLASE RESPONSE 1200 ADHERENCE 880 ALMITRINE 837 25 (OH) D 1200 ADHESION 309 ALOPECIA 973 25 HYDROXYVITAMIN D 1 HYDROXYLASE ADHESIVE GLYCOPROTEINS 880 ALPHA 1-ANTITRYPSIN 1822 1223 ADIPOCYTE 713 ALPHA 1-ANTITRYPSIN DEFICIENCY 2H (OH) D 1200 ADIPOSE TISSUE 1187 813 3 BETAHYDROXYSTEROID ADIPOSITY 713 ALPHA FETOPROTEINS 1296, 1305 DEHYDROGENASE 431 ADOLESCENT BEHAVIOR 10, 19 ALPHA MANNOSIDASE 1241 3 METHYLGLUTACONIC ACID 823 ADOLESCENT PREGNANCY 20 ALPHA TOCOPHEROL 1466 3 METHYLGLUTACONIC ACIDURIA 823 ADRENAL 275, 334 ALTERNATE DAY STEROIDS 1726 3 METHYLGLUTARIC ACID 823 ADRENAL ANDROGEN SECRETION 480 ALTITUDE 273 4 CHANNEL PNEUMOGRAM 1523 ADRENAL CORTICOSTEROIDS 454 ALUMINUM 1595 5' NUCLEOTIDASE 881 ADRENAL HYPERPLASIA 431, 467 ALUMINUM
    [Show full text]
  • Spinal Cord Bioavailability of Methylprednisolone After
    156 Anesthesiology 2000; 92:156–63 © 2000 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Spinal Cord Bioavailability of Methylprednisolone after Intravenous and Intrathecal Administration The Role of P-Glycoprotein Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/92/1/156/398816/0000542-200001000-00027.pdf by guest on 30 September 2021 Kari L. Koszdin, D.V.M.,* Danny D. Shen, Ph.D.,† Christopher M. Bernards, M.D.‡ Background: High-dose intravenously administered methyl- cord bioavailability of methylprednisolone is poor after intra- prednisolone has been shown to improve outcome after spinal venous administration. The studies in knockout mice suggest cord injury. The resultant glucocorticoid-induced immunosup- that this poor bioavailability results from P-glycoprotein–medi- pression, however, results in multiple complications including ated exclusion of methylprednisolone from the spinal cord. sepsis, pneumonia, and wound infection. These complications (Key words: Friend leukemia virus strain B; mdr 1a/1b (2/2); could be reduced by techniques that increase the spinal bio- mice.) availability of intravenously administered methylprednisolone while simultaneously decreasing plasma bioavailability. This HIGH-dose methylprednisolone has been shown to be an study aimed to characterize the spinal and plasma bioavailabil- ity of methylprednisolone after intravenous and intrathecal effective treatment for acute spinal cord injury. The administration and to identify barriers to the distribution of Third National Acute Spinal Cord Injury Study demon- methylprednisolone from plasma into spinal cord. strated that patients receiving an intensive 24- to 48-h Methods: The spinal and plasma pharmacokinetics of intra- 21 21 intravenous methylprednisolone regimen (30-mg/kg bo- venous (30-mg/kg bolus dose plus 5.4 mg z kg z h ) and 21 21 2 2 lus dose plus 5.4 mg z kg z h ) within8hoftheinjury intrathecal (1-mg/kg bolus dose plus 1 mg z kg 1 z h 1) methyl- prednisolone infusions were compared in pigs.
    [Show full text]
  • Clinical Pharmacology of Rocuronium Bromid Clinical
    CLINICAL PHARMACOLOGY OF ROCURONIUM BROMIDE Jerrold H. Levy, MD Professor of Anesthesiology Emory University School of Medicine Division of Cardiothoracic Anesthesiology and Critical Care Emory Healthcare Atlanta, Georgia HISTORICAL PERSPECTIVES OF NEUROMUSCULAR BLOCKING AGENTS INTRODUCTION OF NEW DRUGS 1494 - 1942 Curare 1947 - 1951 Succinylcholine chloride, Gallamine, Metocurine, Decamethonium 1960’s Alcuronium 1970’s Pancuronium bromide, Fazadinium 1980’s Vecuronium bromide, Atracurium besylate 1990 Pipecuronium bromide 1991 Doxacurium chloride 1992 Mivacurium chloride 1994 Rocuronium bromide 1999 Rapacuronium bromide STRUCTURAL CLASSES OF NONDEPOL.ARIZING RELAXANTS • Steroids: Rocuronium bromide, Vecuronium bromide, Pancuronium bromide, Pipecuronium bromide • Naturally occurring benzylisoquinolones: curare, metocurine • Benzylisoquinoliniums: Atracurium besylate, Mivacurium chloride, Doxacurium chloride THE IDEAL RELAXANT • Nondepolarizing • Rapid onset • Dose-dependent duration • No side-effects • Elimination independent of organ function • No active or toxic metabolites ONSET OF PARALYSIS IS AFFECTED BY: • Dose (relative to ED95) • Potency (number of molecules) • Keo (chemistry/blood flow) • Clearance • Age PHARMACODYNAMICS OF ROCURONIUM BROMIDE ONSET OF ROCURONIUM BROMIDE Onset: rapid to intermediate (dose dependent) TRACHEAL INTUBATION Pre-Medication Meperidine 1 mg/kg Atropine 0.01 mg/kg Induction Propofol to 2.5 mg/kg Alfentanil to 0.25 mg/kg Rocuronium bromide 0.6 mg/kg OR Succinylcholine chloride 1 mg/kg Intubation 60 sec.
    [Show full text]